What We're Reading, July 12, 2016: Oregon's Health CO-OP to close down by the end of July; experts discuss fairer ways to decide on drug pricing; and gender bias in physician salaries at academic institutions.
Oregon’s Health CO-OP is calling it a day. Come August, the state of Oregon will have only 2 carriers selling health plans for individuals for the year 2017, and 20,600 individuals who were enrolled through the CO-OP have now been left scampering to find a new plan. According to The Bend Bulletin, the Oregon Department of Consumer and Business Services took the action to shut down the CO-OP following a revelation by CMS that the CO-OP owes $900,000 to the federal risk adjustment program, instead of receiving $5 million from the program.
The drug price debate needs an overhaul and a fresh outlook, according to Kavita Patel, MD, and Scott Gottlieb, MD, who write in a recent Health Affairs blog. Patel and Gottlieb propose an amalgamation of the European model, where the government sets the drug price, with outcomes-based pricing—this, they believe, would keep the wheels of innovation rolling. With the CMS proposal to move toward value-based pricing arrangements as early as 2017, we would need new regulations to clarify how drug makers, insurance plans, and health systems can rationalize value-based and indication-based contract, they write.
Gender bias in compensation continues to plague every aspect of society, around the globe, and, according to a new study in JAMA Internal Medicine, physicians are no exception to this phenomenon. The study found an absolute difference of $51,315 in the average annual unadjusted salaries of female versus male academic physicians, with the female physicians earning lower. This trend, however, varied across specialties, institutions, and faculty ranks. Full professors who were female, for example, had comparable compensation with their male counterparts. Other variables that influenced their earnings included years of experience, total publications, and clinical trial participation.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More